• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vaxxinity, Inc. - Class A Common Stock (NQ: VAXX )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EDT, May 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Vaxxinity, Inc. - Class A Common Stock

    < Previous 1 2 3 4 5 6 Next >
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024
    UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson’s patients 
    From Vaxxinity, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Recap: Vaxxinity Q3 Earnings
    Via Benzinga
    Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
    From Vaxxinity, Inc.
    Via GlobeNewswire
    Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024
    From Vaxxinity, Inc.
    Via GlobeNewswire
    Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida
    From Vaxxinity, Inc.
    Via GlobeNewswire
    Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida
    From Vaxxinity, Inc.
    Via GlobeNewswire
    Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference
    From Vaxxinity, Inc.
    Via GlobeNewswire
    Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
    Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this  
    Via Benzinga
    Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
    Biotech companies are edging closer to finding the answers behind Alzheimer's disease. 
    Via Investor's Business Daily
    Vaxxinity to Present at Upcoming November Medical and Investor Conferences
    From Vaxxinity, Inc.
    Via GlobeNewswire
    Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update
    From Vaxxinity, Inc.
    Via GlobeNewswire
    Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023
    Via Benzinga
    Stocks That Hit 52-Week Lows On Thursday
      On Thursday, 369 companies hit new 52-week lows. 
    Via Benzinga
    Vaxxinity to Present at Upcoming Investor Conferences in September
    From Vaxxinity, Inc.
    Via GlobeNewswire
    Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease
    From Vaxxinity, Inc.
    Via GlobeNewswire
    Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update
    From Vaxxinity, Inc.
    Via GlobeNewswire
    Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director
    From Vaxxinity, Inc.
    Via GlobeNewswire
    Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s Patients
    From Vaxxinity, Inc.
    Via GlobeNewswire
    Vaxxinity Touts Encouraging Data From Early-Stage Parkinson's Vaccine Trial
    Vaxxinity Inc (NASDAQ: VAXX) unveiled results from Part B of its Phase 1 clinical trial of UB-312, an investigational  
    Via Benzinga
    Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Disease
    From Vaxxinity, Inc.
    Via GlobeNewswire
    Recap: Vaxxinity Q1 Earnings
    Vaxxinity (NASDAQ:VAXX) reported its Q1 earnings results on Tuesday, May 9, 2023 at 08:00 AM. Here's what investors need to know about the announcement. Earnings Vaxxinity beat estimated earnings by... 
    Via Benzinga
    Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update
    From Vaxxinity, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April
    From Vaxxinity, Inc.
    Via GlobeNewswire
    Vaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updates
    From Vaxxinity, Inc.
    Via GlobeNewswire
    Vaxxinity Joins TransCelerate Research and Development Consortium
    From Vaxxinity, Inc.
    Via GlobeNewswire
    Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia
    From Vaxxinity, Inc.
    Via GlobeNewswire
    Vaxxinity to Present at Upcoming March Scientific and Medical Conferences
    Vaxxinity to present new preclinical data on anti-tau Alzheimer’s vaccine candidate VXX-301 at AD/PD International Conference 
    From Vaxxinity, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.